Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Coronavirus COVID-19 Regulation

COVID-19: EMA Makes Scientific Advice Free & Fast For Drug, Vaccine Developers

  • News

Executive Summary

The European Medicines Agency has waived its fee for scientific advice for developers of potential vaccines and treatments for the coronavirus

You may also be interested in...



New Powers For EMA Under EU ‘Future Proofing’ Plans

A new legislative proposal is seeking to empower the European Medicines Agency in tracking potential shortages of drugs and medical devices and enable the agency to play a greater role in coordinating clinical trials and vaccine research during health emergencies.

EMA Clarifies Fast-Track Mechanisms For COVID-19 Medicines & Vaccines

From speeding up PIP agreements to starting rolling reviews, the European Medicines Agency has explained how it is accelerating its regulatory procedures for COVID-19 treatments and vaccines.

Upstaza: First Gene Therapy For Ultra-Rare Disorder AADC Deficiency Receives English Funding

The single-dose gene therapy for aromatic L-amino acid decarboxylase in children is to be made available on the National Health Service following a confidential commercial deal between NHS England and PTC Therapeutics.

Table

View full table

Topics

Tags:
Europe Coronavirus COVID-19 Regulation
Latest Headlines

Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding

Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule

See All
UsernamePublicRestriction

Register

PS141842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By